查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951875

鐮狀細胞貧血治療市場分析及預測（至2035年）：按類型、產品類型、技術、應用、最終用戶、採用情況、開發階段、設備和解決方案分類

Sickle-cell Anemia Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Deployment, Stage, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 388 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

鐮狀細胞貧血治療市場預計將從2024年的25億美元成長到2034年的56億美元，複合年成長率約為10.1%。鐮狀鐮狀症狀的各種治療方法，例如基因療法、輸血和藥物治療。基因研究的進步和公眾意識的提高是推動該市場成長的主要因素，其重點在於改善患者的治療效果和生活品質。對更有效、更具針對性的治療方法的需求正在推動創新治療方法的發展。

鐮狀細胞疾病治療市場正經歷強勁成長，這主要得益於基因療法和藥物創新的進步。基因療法憑藉著針對疾病遺傳根源的變革性潛力，引領市場發展。包括 CRISPR-Cas9 在內的基因組編輯技術處於領先地位，預計將提供長期解決方案。製藥業也緊隨其後，羥基脲和沃克洛託等關鍵療法正在幫助患者改善生活品質。 L-麩醯胺酸和單株抗體等新興治療方法也日益受到關注，反映出治療方法的多樣化趨勢。由於成功率的提高和風險的降低，骨髓移植領域重新煥發活力。同時，包括疼痛管理和輸血在內的支持性治療在患者管理中繼續發揮重要作用。遠端醫療和病患監測應用程式等數位健康解決方案的整合，正在提高治療的可及性和藥物依從性，從而進一步推動市場成長。不斷增加的研究經費和策略合作可望促進創新並拓展治療選擇。

市場區隔
類型 基因療法、藥物療法、骨髓移植
產品 羥基脲、L-麩醯胺酸、voxelotor、crizanlizumab
科技 CRISPR-Cas9、慢病毒載體、 RNA干擾
適應症 疼痛管理、輸血、中風預防、急性胸痛症候群
最終用戶 醫院、專科診所、研究機構、居家醫療
實施表格 本機部署、雲端部署、混合式部署
實施階段 臨床前研究、臨床試驗與商業化
醫療設備 輸液幫浦、輸血設備、診斷設備
解決方案 病患監測、治療監測、數據分析

鐮狀細胞疾病治療市場正經歷市場佔有率、定價策略和產品創新方面的動態變化。製藥公司正致力於研發創新治療方法以滿足未被滿足的醫療需求，從而形成了一個競爭激烈的市場格局，新產品頻繁上市。定價策略日益受到價值導向模式的影響，反映出企業對成本效益和病患療效的日益重視。北美仍然是市場主導，而新興地區也受到越來越多的關注和投資。競爭基準分析顯示，市場結構以策略聯盟和併購為特徵，旨在加強產品系列併擴大地域覆蓋範圍。監管影響至關重要，北美和歐洲嚴格的監管準則推動了合規性和創新。各公司正利用法規結構來獲取競爭優勢，並致力於加速新型治療方法的核准流程。儘管面臨研發成本高昂和臨床試驗流程複雜等挑戰，但在基因療法和個人化醫療的推動下，市場仍呈現成長動能。

主要趨勢和促進因素：

由於人們對鐮狀細胞疾病的認知不斷提高以及治療方法的進步，鐮狀細胞疾病治療市場正經歷蓬勃發展。基因療法的發展是關鍵趨勢之一，它有望永久治癒。這些創新治療方法正透過臨床試驗獲得廣泛認可，並有望為患者帶來突破性療效。另一個重要趨勢是製藥公司與研究機構之間合作日益密切的。這些夥伴關係正在加速新型療法的研發，並促進患者更快獲得最先進治療。此外，撒哈拉以南非洲和印度等地區鐮狀細胞病患疾病率的上升也推動了對有效治療方法的需求。政府主導的措施和資金投入也在市場擴張中發揮關鍵作用，改善開發中國家的醫療基礎設施和提高治療可近性的努力創造了新的機會。此外，對個人化醫療的日益重視正在推動標靶治療的發展，從而改善患者預後並提升市場前景。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 基因治療
    • 藥物治療
    • 骨髓移植
  • 市場規模及預測：依產品分類
    • 羥基脲
    • L-麩醯胺酸
    • 體素
    • 克里扎利珠單抗
  • 市場規模及預測：依技術分類
    • CRISPR-Cas9
    • 慢病毒載體
    • RNA干擾
  • 市場規模及預測：依應用領域分類
    • 疼痛管理
    • 輸血
    • 預防中風
    • 急性胸部綜合症
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 居家醫療
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床試驗
    • 已上市
  • 市場規模及預測：依設備分類
    • 點滴幫浦
    • 輸血裝置
    • 診斷設備
  • 市場規模及預測：按解決方案分類
    • 病患監測
    • 治療監測
    • 數據分析

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Global Blood Therapeutics
  • Emmaus Life Sciences
  • CRISPR Therapeutics
  • Bluebird Bio
  • Sangamo Therapeutics
  • Editas Medicine
  • Imara
  • Hema Quest Pharmaceuticals
  • Archer Daniels Midland Company
  • Protagonist Therapeutics
  • Fate Therapeutics
  • Celularity
  • Graphite Bio
  • Beam Therapeutics
  • Intellia Therapeutics
  • Silence Therapeutics
  • Agios Pharmaceuticals
  • Forma Therapeutics
  • Vor Biopharma
  • Mast Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS31579

Sickle-cell Anemia Therapeutics Market is anticipated to expand from $2.5 billion in 2024 to $5.6 billion by 2034, growing at a CAGR of approximately 10.1%. The Sickle-cell Anemia Therapeutics Market encompasses treatments aimed at managing and alleviating symptoms of sickle-cell disease, including gene therapies, blood transfusions, and pharmacological interventions. This market is driven by advancements in genetic research and increased awareness, with a focus on improving patient outcomes and quality of life. The demand for innovative therapies is rising, propelled by the need for more effective and targeted treatment options.

The Sickle-cell Anemia Therapeutics Market is experiencing robust growth, propelled by advances in gene therapy and pharmaceutical innovations. Gene therapy leads the performance landscape, offering transformative potential by targeting the genetic root of the disease. CRISPR-Cas9 and other genome-editing technologies are at the forefront, promising long-term solutions. The pharmaceutical segment follows closely, with hydroxyurea and voxelotor as key therapeutic agents enhancing patient quality of life. Emerging treatments like L-glutamine and monoclonal antibodies are gaining attention, reflecting ongoing diversification in therapeutic approaches. The bone marrow transplant sub-segment is witnessing renewed interest due to improved success rates and reduced risks. Meanwhile, supportive care therapies, including pain management and blood transfusions, continue to play a vital role in patient management. The integration of digital health solutions, such as telemedicine and patient monitoring apps, is enhancing treatment accessibility and adherence, driving further market growth. Increasing research funding and strategic partnerships are expected to fuel innovation and expand therapeutic options.

Market Segmentation
TypeGene Therapy, Pharmacotherapy, Bone Marrow Transplant
ProductHydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
TechnologyCRISPR-Cas9, Lentiviral Vectors, RNA Interference
ApplicationPain Management, Blood Transfusion, Stroke Prevention, Acute Chest Syndrome
End UserHospitals, Specialty Clinics, Research Institutes, Homecare
DeploymentOn-Premise, Cloud-Based, Hybrid
StagePreclinical, Clinical Trials, Commercialized
DeviceInfusion Pumps, Blood Transfusion Devices, Diagnostic Equipment
SolutionsPatient Monitoring, Therapeutic Monitoring, Data Analytics

The Sickle-cell Anemia Therapeutics Market is experiencing dynamic shifts in market share, pricing strategies, and product innovations. Pharmaceutical companies are focusing on innovative therapies to address unmet medical needs, leading to a competitive landscape characterized by frequent new product launches. Pricing strategies are increasingly influenced by value-based models, reflecting the growing emphasis on cost-effectiveness and patient outcomes. North America remains a dominant player in the market, with emerging regions witnessing increased interest and investment. Competition benchmarking reveals a market characterized by strategic collaborations and mergers, aimed at enhancing product portfolios and expanding geographical presence. Regulatory influences are pivotal, with stringent guidelines in North America and Europe driving compliance and innovation. Companies are leveraging regulatory frameworks to gain competitive advantages, focusing on accelerated approval pathways for novel therapies. The market is poised for growth, driven by advancements in gene therapy and personalized medicine, despite challenges such as high R&D costs and complex clinical trial processes.

Geographical Overview:

The Sickle-cell Anemia Therapeutics Market is witnessing varied growth patterns across global regions. North America remains at the forefront, propelled by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies further underpins market growth in this region. Europe follows, with robust government support for rare disease treatments and a strong focus on innovative therapeutic approaches. In the Asia Pacific, the market is expanding rapidly. This growth is driven by increasing awareness and improved healthcare access. Emerging economies like India and China are investing heavily in healthcare infrastructure, creating new growth pockets. Latin America presents untapped potential, with Brazil leading efforts in improving sickle-cell disease management. Meanwhile, the Middle East & Africa are gradually recognizing the importance of addressing sickle-cell anemia, with countries like Nigeria and South Africa showing increased healthcare initiatives. These regions offer lucrative opportunities for market expansion and investment.

The Sickle-cell Anemia Therapeutics Market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, facing increased tariffs on pharmaceutical imports, are prioritizing domestic R&D investments to mitigate reliance on foreign therapeutics. China's strategic pivot towards self-sufficiency is evident in its robust investment in biopharmaceutical innovation, while Taiwan leverages its advanced biotech capabilities amidst geopolitical tensions. The parent market is witnessing a steady growth trajectory globally, driven by heightened demand for innovative treatment modalities. By 2035, the market is anticipated to flourish, contingent on regional collaborations and supply chain resilience. Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy prices, indirectly impacting manufacturing costs and distribution timelines in this sector.

Key Trends and Drivers:

The Sickle-cell Anemia Therapeutics Market is experiencing dynamic growth due to increased awareness and advancements in treatment options. One key trend is the development of gene therapies, which offer the potential for a permanent cure. These innovative treatments are gaining traction as they move through clinical trials, promising transformative outcomes for patients. Another significant trend is the rise in collaborations between pharmaceutical companies and research institutions. These partnerships are accelerating the development of novel therapeutics and facilitating faster access to cutting-edge treatments. Furthermore, the increasing prevalence of sickle-cell disease in regions like Sub-Saharan Africa and India is driving demand for effective therapies. Government initiatives and funding are also playing a crucial role in market expansion. Efforts to improve healthcare infrastructure and access to treatments in developing countries are creating new opportunities. Additionally, the growing focus on personalized medicine is fostering the development of targeted therapies, enhancing patient outcomes and market prospects.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Deployment
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Gene Therapy
    • 4.1.2 Pharmacotherapy
    • 4.1.3 Bone Marrow Transplant
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Hydroxyurea
    • 4.2.2 L-Glutamine
    • 4.2.3 Voxelotor
    • 4.2.4 Crizanlizumab
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 CRISPR-Cas9
    • 4.3.2 Lentiviral Vectors
    • 4.3.3 RNA Interference
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Pain Management
    • 4.4.2 Blood Transfusion
    • 4.4.3 Stroke Prevention
    • 4.4.4 Acute Chest Syndrome
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Homecare
  • 4.6 Market Size & Forecast by Deployment (2020-2035)
    • 4.6.1 On-Premise
    • 4.6.2 Cloud-Based
    • 4.6.3 Hybrid
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Clinical Trials
    • 4.7.3 Commercialized
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Infusion Pumps
    • 4.8.2 Blood Transfusion Devices
    • 4.8.3 Diagnostic Equipment
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Monitoring
    • 4.9.2 Therapeutic Monitoring
    • 4.9.3 Data Analytics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Deployment
      • 5.2.1.7 Stage
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Deployment
      • 5.2.2.7 Stage
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Deployment
      • 5.2.3.7 Stage
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Deployment
      • 5.3.1.7 Stage
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Deployment
      • 5.3.2.7 Stage
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Deployment
      • 5.3.3.7 Stage
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Deployment
      • 5.4.1.7 Stage
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Deployment
      • 5.4.2.7 Stage
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Deployment
      • 5.4.3.7 Stage
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Deployment
      • 5.4.4.7 Stage
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Deployment
      • 5.4.5.7 Stage
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Deployment
      • 5.4.6.7 Stage
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Deployment
      • 5.4.7.7 Stage
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Deployment
      • 5.5.1.7 Stage
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Deployment
      • 5.5.2.7 Stage
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Deployment
      • 5.5.3.7 Stage
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Deployment
      • 5.5.4.7 Stage
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Deployment
      • 5.5.5.7 Stage
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Deployment
      • 5.5.6.7 Stage
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Deployment
      • 5.6.1.7 Stage
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Deployment
      • 5.6.2.7 Stage
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Deployment
      • 5.6.3.7 Stage
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Deployment
      • 5.6.4.7 Stage
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Deployment
      • 5.6.5.7 Stage
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Global Blood Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Emmaus Life Sciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 CRISPR Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bluebird Bio
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sangamo Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Editas Medicine
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Imara
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Hema Quest Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Archer Daniels Midland Company
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Protagonist Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fate Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Celularity
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Graphite Bio
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Beam Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Intellia Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Silence Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Agios Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Forma Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vor Biopharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Mast Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us